Logo

Allogene Therapeutics, Inc.

ALLO

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The compan… read more

Healthcare

Biotechnology

7 years

USD

Exclusive to Premium users

Price

per share adjusted in USD

$1.88

Price

-4.57%

-$0.09

Market Cap

$648.891m

Small

Price/Earnings

-

Premium

3y Avg

Premium

5y Avg

Financial Reports

Key metrics over the past few years and other important metrics. Amounts in USD.

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$0.00

-100.0%

1y CAGR

-72.0%

3y CAGR

-78.9%

5y CAGR
Earnings

-$173.760m

+17.7%

1y CAGR

+14.3%

3y CAGR

-11.0%

5y CAGR
EPS

-$0.77

+25.8%

1y CAGR

+24.9%

3y CAGR

-0.7%

5y CAGR
Book Value

$278.875m

$395.958m

Assets

$117.083m

Liabilities

$81.051m

Debt
Debt to Assets

20.5%

-0.4x

Debt to EBITDA
Free Cash Flow

-$109.526m

+20.9%

1y CAGR

+10.3%

3y CAGR

+5.4%

5y CAGR
No items found.
Press Releases
Statements and updates from the company
↑ TopSummaryPriceFinancialsPress Releases